Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (NASDAQ: FBIOP) stock closed at 11 per share at the end of the most recent trading day (a -5.6% change compared to the prior day closing price) with a volume of 30.88K shares and market capitalization of 1.51B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 93 people. Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock CEO is Lindsay A. Rosenwald.

The one-year performance of Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock stock is -43.15%, while year-to-date (YTD) performance is -37.68%. FBIOP stock has a five-year performance of -39.76%. Its 52-week range is between 6.4 and 21.3147, which gives FBIOP stock a 52-week price range ratio of 33.52%

Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock currently has a PE ratio of -, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of 1.09, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -27.26%, a ROC of -44.48% and a ROE of -130.13%. The company’s profit margin is -%, its EBITDA margin is -264.20%, and its revenue ttm is $59.34 Million , which makes it $17.31 revenue per share.

Of the last four earnings reports from Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock’s next earnings report date is -.

The consensus rating of Wall Street analysts for Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock has a dividend yield of 12.39% with a dividend per share of $2.34 and a payout ratio of -%.

Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock has a Sell technical analysis rating based on Technical Indicators (ADX : 16.27, ATR14 : 0.93, CCI20 : -196.48, Chaikin Money Flow : -0.30, MACD : -0.42, Money Flow Index : 35.22, ROC : -7.17, RSI : 37.76, STOCH (14,3) : 22.37, STOCH RSI : 0.00, UO : 53.04, Williams %R : -77.63), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock in the last 12-months were: